Eikon blames US funding cuts for 15% staff reduction centered on research tools business
Only three months after banking an eye-popping $350 million series D round, Eikon Therapeutics is blaming government funding cuts for its decision to lay off 15% of its employees.
Only three months after banking an eye-popping $350 million series D round, Eikon Therapeutics is blaming government funding cuts for its decision to lay off 15% of its employees.
